NO20080739L - Fremgangsmater for behandling av Epileptogenese - Google Patents
Fremgangsmater for behandling av EpileptogeneseInfo
- Publication number
- NO20080739L NO20080739L NO20080739A NO20080739A NO20080739L NO 20080739 L NO20080739 L NO 20080739L NO 20080739 A NO20080739 A NO 20080739A NO 20080739 A NO20080739 A NO 20080739A NO 20080739 L NO20080739 L NO 20080739L
- Authority
- NO
- Norway
- Prior art keywords
- group
- alkyl
- methods
- phenyl
- optionally substituted
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/325—Carbamic acids; Thiocarbamic acids; Anhydrides or salts thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Emergency Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pain & Pain Management (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
Abstract
Det beskrives metoder for å tilveiebringe neuroproteksjon omfattende administrering til et individ som trenger det av en terapeutisk effektiv mengde av en forbindelse valgt fra gruppen bestående av formel (I) og formel (II), eller et farmasøytisk akseptabelt salt eller en ester derav; der X er ett til fem halogenatomer valgt fra gruppen bestående av fluor, klor, brom og jod; R1-R6 er uavhengig valgt fra gruppen bestående av hydrogen og C1-4 alkyl; der C1-4 alkyl eventuelt er substituert med fenyl (der fenyl eventuelt er substituert med substituenter uavhengig valgt fra gruppen bestående av halogen, C1-4 alkyl, C1-4 alkoksy, amino, nitro og cyano). I II
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US69862505P | 2005-07-12 | 2005-07-12 | |
| PCT/US2006/026277 WO2007008551A2 (en) | 2005-07-12 | 2006-07-07 | Use of 2-phenyl-l, 2-ethanedi0l-(di) carbamates for treating epileptogenesis and epilepsy |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NO20080739L true NO20080739L (no) | 2008-04-10 |
Family
ID=37637731
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20080739A NO20080739L (no) | 2005-07-12 | 2008-02-11 | Fremgangsmater for behandling av Epileptogenese |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US20070021501A1 (no) |
| EP (1) | EP1906946A2 (no) |
| JP (1) | JP2009501223A (no) |
| KR (1) | KR20080028485A (no) |
| CN (1) | CN101309680A (no) |
| AR (1) | AR054550A1 (no) |
| AU (1) | AU2006269462A1 (no) |
| BR (1) | BRPI0613010A2 (no) |
| CA (1) | CA2615127A1 (no) |
| EA (1) | EA200800295A1 (no) |
| EC (1) | ECSP088172A (no) |
| IL (1) | IL188728A0 (no) |
| NO (1) | NO20080739L (no) |
| TW (1) | TW200744575A (no) |
| WO (1) | WO2007008551A2 (no) |
| ZA (1) | ZA200801402B (no) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6005357B2 (ja) * | 2008-05-16 | 2016-10-12 | ノノ インコーポレイテッド | てんかんの治療 |
| US8609849B1 (en) | 2010-11-30 | 2013-12-17 | Fox Chase Chemical Diversity Center, Inc. | Hydroxylated sulfamides exhibiting neuroprotective action and their method of use |
| WO2014142477A1 (en) * | 2013-03-12 | 2014-09-18 | Bio-Pharm Solutions Co., Ltd. | Phenyl carbamate compounds for use in preventing or treating pediatric epilesy and epilesy-related syndromes |
| US8652527B1 (en) | 2013-03-13 | 2014-02-18 | Upsher-Smith Laboratories, Inc | Extended-release topiramate capsules |
| US9101545B2 (en) | 2013-03-15 | 2015-08-11 | Upsher-Smith Laboratories, Inc. | Extended-release topiramate capsules |
| HUE066912T2 (hu) * | 2015-08-24 | 2024-09-28 | Zogenix International Ltd | Lennox-Gastaut szindróma kezelési eljárása fenfluramin alkalmazásával |
| EP3423433B1 (en) * | 2016-02-29 | 2025-12-17 | Bio-Pharm Solutions Co., Ltd. | Sulfamate derivative compounds, processes for preparing them and their uses |
| US20190022166A1 (en) * | 2017-07-18 | 2019-01-24 | Creative Bio-Peptides Inc. | Oral anti-inflammatory peptides to treat epilepsy, seizures and cns disorders |
| USRE50630E1 (en) | 2017-10-31 | 2025-10-14 | Creative BioPeptides, Inc. | Use of an all-D-pentapeptide chemokine antagonist to reduce opioid dose in a person with pain |
| CN109920550A (zh) * | 2018-12-25 | 2019-06-21 | 天津大学 | 一种基于dMRI研究青少年肌阵挛性癫痫的方法 |
| US11510961B2 (en) | 2019-12-19 | 2022-11-29 | Creative Bio-Peptides, Inc. | Methods and compositions for use of a chemokine receptor antagonist peptide to treat addiction, substance abuse disorders or symptoms thereof |
| CN115501344A (zh) * | 2022-09-29 | 2022-12-23 | 重庆医科大学 | 一种铁螯合剂的应用 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3313692A (en) * | 1958-04-21 | 1967-04-11 | Armour Pharma | Method of inducing calming and muscle relaxation with carbamates |
| US3265728A (en) * | 1962-07-18 | 1966-08-09 | Armour Pharma | Substituted phenethyl carbamates |
| US5698588A (en) * | 1996-01-16 | 1997-12-16 | Yukong Limited | Halogen substituted carbamate compounds from 2-phenyl-1,2-ethanediol |
| US6104956A (en) * | 1996-05-31 | 2000-08-15 | Board Of Trustees Of Southern Illinois University | Methods of treating traumatic brain injury by vagus nerve stimulation |
| DK1156798T3 (da) * | 1999-02-09 | 2003-11-03 | Univ Virginia | Felbamat-afledte forbindelser |
| WO2002067924A1 (en) * | 2001-02-27 | 2002-09-06 | Ortho-Mcneil Pharmaceutical, Inc. | Carbamate compounds for use in preventing or treating bipolar disorder |
| DE60210976T2 (de) * | 2001-02-27 | 2007-05-24 | Ortho-Mcneil Pharmaceutical, Inc. | Carbamatverbindungen zur verwendung bei der prävention oder behandlung der bipolaren erkrankung |
-
2006
- 2006-07-06 US US11/481,626 patent/US20070021501A1/en not_active Abandoned
- 2006-07-07 WO PCT/US2006/026277 patent/WO2007008551A2/en not_active Ceased
- 2006-07-07 AU AU2006269462A patent/AU2006269462A1/en not_active Abandoned
- 2006-07-07 KR KR1020087003269A patent/KR20080028485A/ko not_active Withdrawn
- 2006-07-07 EA EA200800295A patent/EA200800295A1/ru unknown
- 2006-07-07 BR BRPI0613010-0A patent/BRPI0613010A2/pt not_active IP Right Cessation
- 2006-07-07 JP JP2008521432A patent/JP2009501223A/ja not_active Withdrawn
- 2006-07-07 EP EP06786434A patent/EP1906946A2/en not_active Withdrawn
- 2006-07-07 CA CA002615127A patent/CA2615127A1/en not_active Abandoned
- 2006-07-07 CN CNA2006800333910A patent/CN101309680A/zh active Pending
- 2006-07-11 TW TW095125162A patent/TW200744575A/zh unknown
- 2006-07-11 AR ARP060102976A patent/AR054550A1/es not_active Application Discontinuation
-
2008
- 2008-01-10 IL IL188728A patent/IL188728A0/en unknown
- 2008-02-11 ZA ZA200801402A patent/ZA200801402B/xx unknown
- 2008-02-11 NO NO20080739A patent/NO20080739L/no not_active Application Discontinuation
- 2008-02-12 EC EC2008008172A patent/ECSP088172A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP1906946A2 (en) | 2008-04-09 |
| JP2009501223A (ja) | 2009-01-15 |
| ZA200801402B (en) | 2009-10-28 |
| AU2006269462A1 (en) | 2007-01-18 |
| US20070021501A1 (en) | 2007-01-25 |
| KR20080028485A (ko) | 2008-03-31 |
| TW200744575A (en) | 2007-12-16 |
| BRPI0613010A2 (pt) | 2010-12-14 |
| AR054550A1 (es) | 2007-06-27 |
| CN101309680A (zh) | 2008-11-19 |
| EA200800295A1 (ru) | 2008-12-30 |
| ECSP088172A (es) | 2008-03-26 |
| WO2007008551A3 (en) | 2008-06-19 |
| CA2615127A1 (en) | 2007-01-18 |
| IL188728A0 (en) | 2008-11-03 |
| WO2007008551A2 (en) | 2007-01-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO20080739L (no) | Fremgangsmater for behandling av Epileptogenese | |
| NO20080738L (no) | Fremgangsmater for neurobeskyttelse | |
| NO20071921L (no) | Fremgangsmater for behandling av epileptogenese og epilepsi | |
| NO20064251L (no) | Benzamidazolderivater og anvendelse derav | |
| CO6180427A2 (es) | Tratamiento de los trastornos generalizados del desarrollo | |
| NO20072444L (no) | Karbamatforbindelser for anvendelse i behandling av neurodegenerative forstyrrelser | |
| NO20080877L (no) | Fremgangsmater for behandling av substansrelaterte forstyrrelser | |
| PE20071132A1 (es) | Compuestos macrociclicos como inhibidores del factor viia | |
| AR054524A1 (es) | Metodos y formas de dosificacion para reducir los efectos secundarios de compuestos de carbamato | |
| EA200701536A1 (ru) | Способы контроля интервала qt | |
| IL157590A0 (en) | Carbamate compounds for use in preventing or treating bipolar disorder | |
| AR064241A1 (es) | Metodos para el tratamiento de la depresion | |
| NO20091658L (no) | Fremgangsmate for behandling av koleitt og vestibulaere lidelser | |
| IL157594A0 (en) | Carbamate compounds for use in preventing or treating anxiety disorders | |
| NO20033801L (no) | Karbamatforbindelser for anvendelse ved forebygging eller behandling av psykotiske forstyrrelser | |
| CO6160292A2 (es) | Metodos de tratamiento de transtornos de comportamiento perturbador 877 | |
| EA201070819A1 (ru) | Соединения n-фенилимидазо[1,2-a]пиридин-2-карбоксамида, их получение и их применени в терапии | |
| ATE555103T1 (de) | Umwandlung von 2-pyrazolinen in pyrazole mithilfe von bromin | |
| EA200700322A1 (ru) | Оксазолидиноны, содержащие оксиндолы, в качестве антибактериальных агентов | |
| NO20040176L (no) | Karbamatforbindelser for anvendelse ved prevensjon eller terapi av neuropatisk smerte og kluster- og migrenehodepineassosiert smerte | |
| TW200701978A (en) | Methods of treating epileptogenesis and epilepsy | |
| MY136733A (en) | Carbamate compounds for use in preventing or treating psychotic disorders | |
| CY1110672T1 (el) | Χρηση των 2- φαινυλ-1,2-αιθανοδιολης- (δι) καρβαμικων για θεραπεια επιληπτογενεσης |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC2A | Withdrawal, rejection or dismissal of laid open patent application |